A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors

Inclusion Criteria:

- Men or women > 18 years old

- Pathologically documented, definitively diagnosed, advanced solid tumor that is
refractory to standard treatment, or which no standard therapy is available, or the
subject refuses standard therapy

- Willing to undergo pre-dose core needle tumor biopsies

- Ability to take oral medications and willing to record daily adherance to
investigational product

- Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Exclusion Criteria:

- Active brain metastases

- Prior bone marrow transplant

- History or presence of hematological malignancies

- Active infection requiring intravenous (IV) antibiotics

- Anti-tumor therapy

- Therapeutic or palliative radiation therapy

- Currently enrolled in another investigational device or drug study